Author

Romel Somwar

Memorial Sloan Kettering Cancer CenterORCID 0000-0002-5282-6889Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Elisa de StanchinaiD· 2 shared Alex KentsisiD· 1 shared Alexander J. PfeiliD· 1 shared Andrea CalifanoiD· 1 shared Andrea M. GazzoiD· 1 shared Andrew L. KungiD· 1 shared Christopher A. Febres‐AldanaiD· 1 shared Daniel CameroniD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Elisa de StanchinaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236

Alexander J. Pfeil, Tom Zhang, Ryan Cheng, Marissa S. Mattar, Juan Luis Gomez Marti, Leo Gili, Rachel Lai, Inna Khodos, Rohan P Master, Jenna-Marie Dix, Andrea M. Gazzo, Kathryn Cecilia Arbour, Elisa de Stanchina, Christopher A. Febres‐Aldana, Marc Ladanyi, , Romel Somwar

This study identifies RRASQ87L and RRAS2Q72L mutations as recurrent oncogenic drivers in lung cancer and shows sensitivity to the pan-RAS inhibitor RMC-6236.

Clinical Cancer Research · Jan 16, 2026Peer-reviewedCancer Biology

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas

Yaniv Kazansky, Helen S. Mueller, Daniel Cameron, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Prabhjot Singh Mundi, Yasumichi Kuwahara, Romel Somwar, Rui Qu, Andrea Califano, Elisa de Stanchina, Filemon S. Dela Cruz, Andrew L. Kung, , Alex Kentsis

The paper identifies ATR as a target for combination EZH2 epigenetic therapy in SMARCB1-deficient sarcomas, showing that EZH2 inhibition promotes DNA damage via PGBD5, and that ATR inhibition enhances therapeutic responses.

Journal of Clinical Investigation · Aug 12, 2025Peer-reviewedCancer Biology